Floatz logo

Vudalimab

Clear Cell Carcinoma

Xencor, Inc.Phase 2Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

13 Active assets in the Clear Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
Dana-Farber Cancer Institute
Phase 2B
Rucaparib
North Eastern German Society of Gynaecological Oncology
Phase 3B
Lorigerlimab
MacroGenics
Phase 2CCC
Dostarlimab
Yonsei University
Phase 2CCC
Inno-206
Yonsei University
Phase 2CCC

View all 20 →

Same molecule, other indications

Vudalimab is also rated in:

castration-resistant prostate carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
cervical carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
metastatic prostate carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →